NOTE TO READER – The news release of Endeavour Silver Corp. dated January 16, 2026, (the “News Release”) has been re-filed on SEDAR. The previously filed News Release had a typographical error on page 3 with respect to the AISC for Terronera. The consolidated AISC remains the same as the previously filed News Release. This news release replaces the previously filed News Release. VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; T ...

Core Viewpoint - Tiziana Life Sciences has successfully closed a registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising gross proceeds of $8.8 million, which will support its clinical trials for intranasal foralumab, its lead candidate [1][3]. Group 1: Offering Details - The offering was conducted without an underwriter or placement agent and was primarily subscribed by senior management and existing shareholders [1]. - Participants in the offering will receive warrants to purchase additional shares at $1.50, potentially raising an additional $10.56 million [1]. - The offering was led by CEO Ivor Elrifi, who purchased 2,400,000 shares, increasing his total holdings to 2,757,848 shares [2]. Group 2: Clinical Development - Proceeds from the offering will enable Tiziana to complete Phase 2 clinical trials for non-active secondary progressive multiple sclerosis (na-SPMS) and multiple system atrophy (MSA) [3]. - Foralumab, the lead candidate, is a fully human anti-CD3 monoclonal antibody that has shown promise in stimulating T regulatory cells when administered intranasally [6][7]. - The drug is currently being tested in a Phase 2a trial, with positive early results reported in an open-label program involving 14 patients [6]. Group 3: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies [8]. - The company's nasal delivery approach aims to enhance the efficacy, safety, and tolerability of immunotherapy compared to traditional intravenous methods [8]. - Tiziana's technology for alternative routes of immunotherapy is patented, with several applications pending, indicating potential for a broad pipeline of therapies [8].

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix’s commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the ...

SPARTANBURG, S.C., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Denny’s Corporation (the “Company” or “Denny’s”) (NASDAQ: DENN), owner and operator of Denny’s Inc. and Keke’s Inc., today announced the successful completion of its previously announced acquisition by TriArtisan Capital Advisors LLC (“TriArtisan”), Treville Capital Group (“Treville”) and Yadav Enterprises, Inc. (“Yadav Enterprises”). The transaction closed following approval by Denny’s stockholders as well as satisfaction of all required regulatory and c ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])* in patients treated with epc ...

Core Insights - Rackspace Technology has achieved VMware Sovereign Cloud Partner Status, enhancing its capability to manage sensitive data for UK organisations [1][5] - The company's Sovereign Services provide a fully managed private cloud platform tailored for organisations needing strict data control [2][3] - Rackspace's digital Sovereign Cloud aims to optimize private cloud architecture for mission-critical applications, ensuring performance and security [3] Company Overview - Rackspace Technology specializes in end-to-end hybrid cloud and AI solutions, supporting customers throughout their cloud journey [6] - The company collaborates with UK public sector organisations, financial services, and healthcare providers to deliver comprehensive cloud solutions [4] Service Features - The Sovereign Services are built on VMware technologies and operated from UK data centres, ensuring high availability and integrated security [2] - The VMware Sovereign Cloud Partner Status signifies compliance with local data sovereignty and privacy regulations [5]

January 16, 2026 – 6.30 PM CET Regulated information Agfa receives final expert ruling on receivable related to sale of Offset Solutions division to Aurelius Mortsel, Belgium – January 16, 2026 – 6.30 p.m. CET Agfa has received the final report of the independent expert regarding the outstanding receivable under the share purchase agreement that was signed with Aurelius Group for the sale of Agfa’s Offset Solutions division. In August 2022, Agfa announced the signing of a share purchase agreement with ...

JACKSONVILLE, Fla., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced it is offering new homes in Mariposa at EverRange, a new luxury home community in Jacksonville, Florida. Toll Brothers will offer four thoughtfully designed single-family home designs in this exclusive community within the highly anticipated EverRange master plan. Toll Brothers homes in Mariposa at EverRange feature single-story and two-story homes ranging from ...

Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of careNovartis plans to submit to health authorities globally starting in early 2026Ianalumab has potential to become first targeted treatment for this autoimmune disease with significant unmet need Basel, January 16, 2026 – Novartis today announced that the U ...

Elis announces the termination of the liquidity contract Puteaux, 16 January 2026 – Elis, the global leader in circular services at work, announces the termination of the liquidity contract agreed on December 1, 2023 with Oddo BHF (Group Natixis). The contract had been suspended since January 9, 2026, and was terminated by Elis with effect from January 14, 2026, in connection with the continuation of its share buyback program. As of January 14, 2026, the following resources appeared on the liquidity accoun ...